Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Xeomin for Post-Stroke Lower Limb Spasticity
NCT04544280Completed
- Start
- Sep 2018
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in spasticity. Primary endpoint: Temporo-spatial parameters of gait. Started Sep 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT04544280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544280.